Christopher B O'Donnell

US Patent:

20140045790, Feb 13, 2014

Filed:

Oct 15, 2013

Appl. No.:

14/053924

Inventors:

Douglas Scott Johnson - Concord MA, US
Chakrapani Subramanyam - South Glastonbury CT, US
Christopher John O'Donnell - Mystic CT, US
Christopher William am Ende - Mystic CT, US
Benjamin Adam Fish - Groton CT, US
Michael Eric Green - Boston MA, US
Patrick Bradley Mullins - East Lyme CT, US
Cory Michael Stiff - New London CT, US
Tuan Phong Tran - Ledyard CT, US
Thayalan Navaratnam - Scarborough, CA

Assignee:

Pfizer Inc. - Groton CT

International Classification:

C07D 471/04
C07D 401/04
C07F 7/08
C07D 491/048
A61K 31/695
A61K 31/4985
A61K 45/06

US Classification:

514 63, 544349, 514249, 5462741, 544229

Abstract:

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ias defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

US Patent:

20210285050, Sep 16, 2021

Filed:

Jul 3, 2019

Appl. No.:

17/258084

Inventors:

- Washington DC, US
Scott M. Damrauer - Philadelphia PA, US
Christopher J. O'Donnell - Boston MA, US
Philip S. Tsao - Palo Alto CA, US
Sekar Kathiresan - Boston MA, US
Daniel J. Rader - Philadelphia PA, US
Peter W.F. Wilson - Decatur GA, US
Themistocles L. Assimes - Palo Alto CA, US

International Classification:

C12Q 1/6883
A61K 31/4709
C12N 9/22
C12N 15/11
A61K 31/7088
A61K 38/46
C12N 15/113

Abstract:

Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a T cell receptor (TCR) antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Disclosed are methods of making a CART cell comprising obtaining a cell from a subject diagnosed with T cell lymphoma; determining the sequence of the TCR on the cell; and transducing a T cell with a vector comprising a nucleic acid sequence that encodes a CAR polypeptide, wherein the CAR polypeptide comprises a TCR antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the TCR antigen binding domain is specific to a subsequence of the sequence of the TCR on the cell identified in the step of determining the sequence of the TCR

US Patent:

20160024088, Jan 28, 2016

Filed:

Oct 7, 2015

Appl. No.:

14/877118

Inventors:

- New York NY, US
Douglas Scott Johnson - Concord MA, US
Chakrapani Subramanyam - South Glastonbury CT, US
Christopher John O'Donnell - Mystic CT, US
Christopher William am Ende - Mystic CT, US
Michael Eric Green - Boston MA, US
Nandini Chaturbhai Patel - Waban MA, US
Cory Michael Stiff - Salem CT, US
Tuan Phong Tran - Ledyard CT, US
Gregory Wayne Kauffman - East Greenwich RI, US
Antonia Friederike Stepan - Brookline MA, US
Patrick Robert Verhoest - Newton MA, US

International Classification:

C07D 471/04

Abstract:

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ias defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

US Patent:

20150072990, Mar 12, 2015

Filed:

Nov 17, 2014

Appl. No.:

14/543020

Inventors:

- New York NY, US
Douglas Scott Johnson - Concord MA, US
Chakrapani Subramanyam - South Glastonbury CT, US
Christopher John O'Donnell - Mystic CT, US
Christopher William am Ende - Mystic CT, US
Michael Eric Green - Boston MA, US
Nandini Chaturbhai Patel - Waltham MA, US
Cory Michael Stiff - New London CT, US
Tuan Phong Tran - Ledyard CT, US
Gregory Wayne Kauffman - East Greenwich RI, US
Antonia Friederike Stepan - Providence RI, US
Patrick Robert Verhoest - Newton MA, US

International Classification:

C07D 471/04

US Classification:

514249

Abstract:

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ias defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

US Patent:

20140088111, Mar 27, 2014

Filed:

Sep 19, 2013

Appl. No.:

14/031163

Inventors:

- Groton CT, US
Douglas Scott Johnson - Concord MA, US
Chakrapani Subramanyam - South Glastonbury CT, US
Christopher John O'Donnell - Mystic CT, US
Christopher William am Ende - Mystic CT, US
Michael Eric Green - Boston MA, US
Nandini Chaturbhai Patel - Waltham MA, US
Cory Michael Stiff - New London CT, US
Tuan Phong Tran - Ledyard CT, US
Gregory Wayne Kauffman - East Greenwich RI, US
Antonia Friederike Stepan - Providence RI, US
Patrick Robert Verhoest - Newton MA, US

Assignee:

Pfizer Inc. - Groton CT

International Classification:

C07D 471/04

US Classification:

514249, 544349

Abstract:

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ias defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.